Latest Defense News

xReality Group (XRG) reports a landmark FY25 with 36% revenue growth driven by its Operator XR platform and a major US law enforcement contract. The company’s strategic shift towards immersive training technology signals robust momentum into FY26.

4DMedical reports a robust 56% revenue increase in FY2025, driven by SaaS expansion and strategic partnerships, while advancing FDA clearance for its innovative CT – VQ™ lung imaging software.

Harvey Norman Holdings Limited reported robust FY25 results with strong sales growth, a significant profit increase, and a major boost from property revaluations. The company’s integrated retail, franchise, and property model continues to underpin its expansion and resilience.

Amaero Ltd has launched a $3 million Share Purchase Plan offering eligible shareholders in Australia and New Zealand the chance to buy new shares at $0.40 each, matching a recent placement price. The offer opens on 29 August and closes on 19 September 2025.

Orbital Corporation Limited posted a $4.3 million net loss for FY25, reflecting a revenue decline amid production transitions. The company secured a $3 million capital raise to support new UAV engine development and expand its global footprint.

WhiteHawk Limited reports an 8.6% revenue increase and a 26% reduction in net loss for H1 2025, alongside new US government contracts and a $1.56 million capital raise.

Civmec Limited reported a 21.6% drop in revenue and a 34% fall in net profit for FY2025, reflecting the impact of completed contracts. Despite this, the company maintained steady margins and increased its cash reserves, signaling resilience and ongoing growth potential.

Lynas Rare Earths reported FY25 results featuring record NdPr output and the first commercial heavy rare earths production outside China, alongside a $750 million equity raise to fund its ambitious Towards 2030 growth strategy.

Micro-X reported FY25 revenue of $13.1 million, underpinned by significant US government contracts and pioneering 3D head CT imaging technology, setting the stage for clinical trials and commercial expansion.

Cyclopharm Limited reports a 26% revenue jump to $15.42 million in H1 2025, driven by rapid U.S. expansion and extended patent protections for its Technegas® lung imaging technology.

archTIS Limited has reported FY25 results with solid ARR growth and completed a transformative acquisition of Spirion LLC, significantly boosting its US market presence and product suite. The company is raising $20.5 million to fund this expansion and accelerate growth.

archTIS Limited has acquired Spirion LLC’s technology, customers, and employees for A$15.7 million, significantly expanding its U.S. presence and product portfolio in data security. The deal adds A$17 million in annual recurring revenue and brings new cross-selling opportunities across a blue-chip customer base.